Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Dr. Sherer discusses results from key studies reported at the 2020 International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2020 Virtual), including studies on long-term 2-drug and 3-drug antiretroviral therapy, newer 3-drug regimens in patients with baseline NRTI resistance, investigational HIV treatment approaches, and important comoribidities in patients with HIV, including COVID-19.
Content based on a CME program supported by independent educational grants from Gilead Sciences, Inc., Janssen Therapeutics, Division of Janssen Products, LP, and ViiV Healthcare.
Link to full program: www.clinicaloptions.com/2020Glasgow
Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
This program has been made available online.
Clinical Care Options (CCO) commentary from Dr Darrell Tan on the dosing options for long-acting injectable cabotegravir plus rilpivirine for HIV treatment
Drs. Jean Rene Anderson and William Short speak to the balancing act when considering HIV treatments during pregnancy, from Clinical Care Options (CCO)
Understand medical, social, and emotional challenges faced by older PWH, from Clinical Care Options (CCO)
Safety and efficacy of broadly neutralizing antibody VRC01 with early ART in infants with HIV, reported by Clinical Care Options (CCO) from AIDS 2022